1
|
McGreevy D, Abu-Zidan F, Sadeghi M, Pirouzram A, Toivola A, Skoog P, Idoguchi K, Kon Y, Ishida T, Matsumura Y, Matsumoto J, Reva V, Maszkowski M, Bersztel A, Caragounis E, Falkenberg M, Handolin L, Oosthuizen G, Szarka E, Manchev V, Wannatoop T, Chang S, Kessel B, Hebron D, Shaked G, Bala M, Coccolini F, Ansaloni L, Dogan E, Manning J, Hibert-Carius P, Larzon T, Nilsson K, Hörer T. Feasibility and Clinical Outcome Of REBOA in Patients With Impending Traumatic Cardiac Arrest. Eur J Vasc Endovasc Surg 2019. [DOI: 10.1016/j.ejvs.2019.09.443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
2
|
Sadeghi M, Nilsson KF, Larzon T, Pirouzram A, Toivola A, Skoog P, Idoguchi K, Kon Y, Ishida T, Matsumara Y, Matsumoto J, Reva V, Maszkowski M, Bersztel A, Caragounis E, Falkenberg M, Handolin L, Kessel B, Hebron D, Coccolini F, Ansaloni L, Madurska MJ, Morrison JJ, Hörer TM. The use of aortic balloon occlusion in traumatic shock: first report from the ABO trauma registry. Eur J Trauma Emerg Surg 2018; 44:491-501. [PMID: 28801841 PMCID: PMC6096626 DOI: 10.1007/s00068-017-0813-7] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 07/04/2017] [Indexed: 11/09/2022]
Abstract
PURPOSE Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a technique for temporary stabilization of patients with non-compressible torso hemorrhage. This technique has been increasingly used worldwide during the past decade. Despite the good outcomes of translational studies, clinical studies are divided. The aim of this multicenter-international study was to capture REBOA-specific data and outcomes. METHODS REBOA practicing centers were invited to join this online register, which was established in September 2014. REBOA cases were reported, both retrospective and prospective. Demographics, injury patterns, hemodynamic variables, REBOA-specific data, complications and 30-days mortality were reported. RESULTS Ninety-six cases from 6 different countries were reported between 2011 and 2016. Mean age was 52 ± 22 years and 88% of the cases were blunt trauma with a median injury severity score (ISS) of 41 (IQR 29-50). In the majority of the cases, Zone I REBOA was used. Median systolic blood pressure before balloon inflation was 60 mmHg (IQR 40-80), which increased to 100 mmHg (IQR 80-128) after inflation. Continuous occlusion was applied in 52% of the patients, and 48% received non-continuous occlusion. Occlusion time longer than 60 min was reported as 38 and 14% in the non-continuous and continuous groups, respectively. Complications, such as extremity compartment syndrome (n = 3), were only noted in the continuous occlusion group. The 30-day mortality for non-continuous REBOA was 48%, and 64% for continuous occlusion. CONCLUSIONS This observational multicenter study presents results regarding continuous and non-continuous REBOA with favorable outcomes. However, further prospective studies are needed to be able to draw conclusions on morbidity and mortality.
Collapse
Affiliation(s)
- M Sadeghi
- Västmanlands Hospital Västerås, Department of Vascular Surgery, Örebro University, Örebro, Sweden
| | - K F Nilsson
- Department of Cardiothoracic and Vascular Surgery, Faculty of Medicine and Health, Örebro University Hospital, 701 85, Örebro, Sweden
| | - T Larzon
- Department of Cardiothoracic and Vascular Surgery, Faculty of Medicine and Health, Örebro University Hospital, 701 85, Örebro, Sweden
| | - A Pirouzram
- Department of Cardiothoracic and Vascular Surgery, Faculty of Medicine and Health, Örebro University Hospital, 701 85, Örebro, Sweden
| | - A Toivola
- Department of Cardiothoracic and Vascular Surgery, Faculty of Medicine and Health, Örebro University Hospital, 701 85, Örebro, Sweden
| | - P Skoog
- Department of Vascular Surgery, Örebro University, Örebro, Sweden
| | - K Idoguchi
- Senshu Trauma and Critical Care Center, Rinku General Medical Center, Izumisano, Japan
| | - Y Kon
- Emergency and Critical Care Center, Hachinohe City Hospital, Hachinohe, Japan
| | - T Ishida
- Emergency and Critical Care Center, Ohta Nishinouchi Hospital, Koriyama, Japan
| | - Y Matsumara
- Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
- R Adams Cowley Shock Trauma Center, University of Maryland, College Park, MD, USA
| | - J Matsumoto
- Department of Emergency and Critical Care Medicine, St Marianna University School of Medicine, Kawasaki, Japan
| | - V Reva
- Department of War Surgery, Kirov Military Medical Academy, Saint Petersburg, Russia
- Dzhanelidze Research Institute of Emergency Medicine, Saint Petersburg, Russia
| | - M Maszkowski
- Västmanlands Hospital Västerås, Department of Vascular Surgery, Örebro University, Örebro, Sweden
| | - A Bersztel
- Västmanlands Hospital Västerås, Department of Vascular Surgery, Örebro University, Örebro, Sweden
| | - E Caragounis
- Sahlgrenska University Hospital, Department of Surgery, University of Gothenburg, Gothenburg, Sweden
| | - M Falkenberg
- Department of Radiology, Örebro University, Örebro, Sweden
| | - L Handolin
- Helsinki University Hospital, Department of Orthopedics and Traumatology, University of Helsinki, Helsinki, Finland
| | - B Kessel
- Department of Surgery, Hillel Yaffe Medical Centre, Hadera, Israel
| | - D Hebron
- Department of Surgery, Hillel Yaffe Medical Centre, Hadera, Israel
| | - F Coccolini
- Department of Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - L Ansaloni
- Department of Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - M J Madurska
- Department of Vascular Surgery, Queen Elizabeth University Hospital, Glasgow, UK
| | - J J Morrison
- Department of Vascular Surgery, Queen Elizabeth University Hospital, Glasgow, UK
| | - T M Hörer
- Department of Cardiothoracic and Vascular Surgery, Faculty of Medicine and Health, Örebro University Hospital, 701 85, Örebro, Sweden.
| |
Collapse
|
3
|
Viklund J, Bersztel A, Karkamanis A, Jonason T, Henriksen E, Trollvad L, Karacagil S, Hellberg A. ABI IS AN EFFECTIVE PREDICTOR FOR CAROTID AND RENAL ARTERY STENOSIS. ATHEROSCLEROSIS SUPP 2008. [DOI: 10.1016/s1567-5688(08)70600-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Abstract
Antibodies play a crucial role in the rejection of an organ that has been transplanted between different animal species, i.e. xenotransplantation. In previous work, we have induced a state of humoral tolerance where mouse-to-rat heart grafts continued to beat under ciclosporine A monotherapy. Initially, a combined treatment with ciclosporine A and 15-deoxyspergualin was given. This state of tolerance could not be reproduced when the vascularised heart graft was replaced with a free tissue graft or xenogeneic blood transfusions. To gain further insight into the humoral response against mouse antigens, we studied the antibody production in naive rats and rats challenged with heart transplants, heart cells, mononuclear cells (MNC) and erythrocytes from mice. Rats not challenged with any mouse cells or organs had a moderate amount of antibodies targeted against mouse MNC as well as rosette-forming cells in the spleen targeted against mouse erythrocytes. A challenge with either mouse MNC or erythrocytes lead to immunisation with antibodies of both IgM and IgG subtype directed against both MNC and erythrocytes. Antibody titres against mouse erythrocytes in animals challenged with MNC were not detectable until day 7, whereas antibody titres against mouse MNC in animals challenged with erythrocytes were detected on day 1. Immunisation with mouse erythrocytes raised the titre of rosette-forming cells in the spleen compared with naive rats (P < 0.05). Our data indicate that different xenogeneic antigens in the mouse-to-rat system are shared between heart cells, MNC and erythrocytes; however, the immunisation patterns differ regarding the time when antibodies are first detected.
Collapse
Affiliation(s)
- A Bersztel
- Department of Transplantation Surgery, Uppsala University Hospital, Uppsala, Sweden
| | | | | | | | | |
Collapse
|
5
|
Bersztel A, Johnsson C, Björkland A, Tufveson G. Pretransplant xenogeneic blood transfusions reduce the humoral response in a mouse-to-rat heart transplantation model. Scand J Immunol 2003; 57:246-53. [PMID: 12641653 DOI: 10.1046/j.1365-3083.2003.01224.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A mouse heart transplanted to a rat is rejected promptly 3 days after transplantation, independent of whether cyclosporin A (CyA) is used as an immunosuppressant or not. Adding a short course of deoxyspergualin (DSG) initially, in addition to continuous CyA treatment, results in long-term graft survival and permits retransplantation during CyA monotherapy. In this paper, we have explored the possibility of substituting the initial heart transplant with blood transfusions. Lymphocyte-enriched blood transfusions combined with CyA and an initial course of DSG proved to lower or eliminate the haemagglutinating antibody titre normally seen in acute vascular xenorejection. The therapy, however, did not prolong the mean survival of the cardiac xenograft, but the same treatment protocol could result in either hyperacute rejection or prolonged survival of up to 11 days. In conclusion, this and earlier studies propose that a humoral unresponsiveness can be induced if the recipient vascular circulation is exposed to a xenoantigen in a mouse-to-rat combination.
Collapse
Affiliation(s)
- A Bersztel
- Department of Transplantation Surgery, University Hospital, Uppsala, Sweden
| | | | | | | |
Collapse
|
6
|
Bersztel A, Andersson A, Björkland A, Tufveson G, Johnsson C. Concordant xenotransplantation--non-vascularized pancreatic islets are more difficult to regraft than the vascularized heart. Xenotransplantation 2000; 7:118-28. [PMID: 10961296 DOI: 10.1034/j.1399-3089.2000.00049.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We have previously demonstrated that it is possible to perform retransplantation of a xenogeneic heart (mouse-to-rat) using cyclosporine A as monotherapy, provided that the first heart is transplanted under a short course of deoxyspergualin (DSG). If DSG is omitted, the first heart is rejected within four days and the second heart succumbs to hyperacute rejection within minutes. A mouse heart as first graft does not protect a consecutive pancreatic islet graft, although the heart continues to function after rejection of the cellular graft. One explanation for this discrepancy may be the fact that cellular grafts, as pancreatic islets, lack an endothelial lining. We have, therefore, further investigated possible differences between vascularized and non-vascularized xenografts regarding their capacity to induce unresponsiveness. The use of pancreatic islets as primary graft neither accelerated nor decelerated the speed of rejection of the vascularized heart used as secondary graft. Furthermore, hemagglutinating and cytotoxic antibody titres responded in the same manner as in naive rats transplanted with a mouse heart. Retransplantation with pancreatic islets also resulted in complete rejection of both the primary and secondary grafts. Thus, the lack of unresponsiveness cannot simply be explained by differences, between the pancreatic and cardiac tissues, in antigen expression. In addition, intraperitoneal transplantation of mouse heart cells as primary graft resulted in rejection of a secondary cardiac graft after three days. However, it cannot be totally excluded that the time of antigen exposure had an impact on these results. In conclusion, our previous and present studies suggest that the presence of an intact vascular bed, both in the first and second graft, is necessary to create a state of unresponsiveness. Because the pancreatic islets lack an endothelial lining, they do not benefit from an unresponsiveness of the immune system. Neither are they able to induce such an unresponsiveness.
Collapse
Affiliation(s)
- A Bersztel
- Department of Transplantation Surgery, University Hospital, Uppsala, Sweden
| | | | | | | | | |
Collapse
|
7
|
Abstract
Long-term survival of a concordant xenograft can be achieved by using cyclosporine (CyA) and deoxyspergualin (DSG) for immunosuppression. We have demonstrated in a mouse-to-rat heterotopic heart transplantation model that DSG treatment can be stopped after 4 weeks with the grafts remaining beating. In this investigation we have sequentially characterized the morphological changes and infiltrating cells in the transplanted hearts. Graft recipients were killed 9 days, 28 days and 56 days after transplantation. At days 9 and 28, the grafts exhibited a well-preserved morphology, with infiltrating cells restricted only to the periphery. These cells stained positive for rat MHC class II antigens, the ED1-macrophage marker and the CD4 antigen, and were thus considered to be macrophages. In comparison, grafts harvested at day 56 had signs of interstitial fibrosis and some arteries showed pronounced intimal thickening. There was a moderate infiltrate of cells both in the peripheral and central parts of the graft, consisting mainly of MHC class II+/ CD4+/ED1+ macrophages. Very few T cells and NK cells were noticed. Termination of DSG after 28 days does not trigger a humoral rejection. However, the grafts exhibit morphological changes equivalent to those seen in chronic allograft rejection. In addition, the characteristics of the infiltrating cells conformed with cellular infiltrates associated with chronic allograft rejection. Hence, this model could in the future prove to be useful for studies of mechanisms involved in chronic xenograft rejection.
Collapse
Affiliation(s)
- A Bersztel
- Department of Transplantation Surgery, University Hospital, Uppsala, Sweden
| | | | | | | |
Collapse
|
8
|
Johnsson C, Andersson A, Bersztel A, Karlsson-Parra A, Gannedahl G, Tufveson G. Successful retransplantation of mouse-to-rat cardiac xenografts under immunosuppressive monotherapy with cyclosporine. Transplantation 1997; 63:652-6. [PMID: 9075833 DOI: 10.1097/00007890-199703150-00007] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The present study was undertaken to investigate whether retransplantation with a second xenograft, from the same species as the primary graft, is possible to achieve using only moderate immunosuppression. Heterotopic mouse-to-rat cardiac transplantations were performed, and the recipients were treated with 15-deoxyspergualin (DSG) and cyclosporine (CsA) at high doses for days -1 to 4 and at moderate doses for days 5 to 28. From day 29 and onward, the immunosuppressive protocol consisted of daily oral administration of CsA 10 mg/kg as monotherapy. Animals that had beating grafts when DSG treatment was stopped were retransplanted 56-154 days after the primary transplantation, either with a vascularized graft (heart) or with nonvascularized graft (pancreatic islets), under continued therapy with CsA. Six of 10 secondary cardiac xenografts functioned for more than 50 days and were harvested beating after 60-100 days. In contrast, nonimmunosuppressed or DSG-treated rats are known to reject a second cardiac mouse graft hyperacutely. The unresponsiveness was confined to cardiac tissue, as the pancreatic islets, transplanted under the kidney capsule, were totally rejected after 14 days. Long-term functioning cardiac xenografts, primary and secondary, had a well-preserved morphology, and infiltrating mononuclear cells were found just in the periphery of the grafts. A majority of these cells were macrophages expressing the ED1, but not the ED2, antigen. No deposition of IgG or complement was seen in any of the graft vessels, whereas a slight deposition of IgM was observed in some vessels of both primary and secondary grafts. In conclusion, we have demonstrated that unresponsiveness can be induced by effective immunosuppression of the recipient at the time of the initial transplantation, so that retransplantation with a second xenograft can be performed successfully under single-drug immunosuppressive therapy with CsA.
Collapse
Affiliation(s)
- C Johnsson
- Department of Transplantation Surgery, University Hospital, Uppsala, Sweden
| | | | | | | | | | | |
Collapse
|
9
|
Bersztel A, Wadström J, Tufveson G, Gannedahl G, Bengtsson M, Bergström C, Frödin L, Claesson K, Wikström B, Wahlberg J. Is kidney transplantation in sensitized recipients justified? Transpl Int 1996. [DOI: 10.1111/j.1432-2277.1996.tb01683.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Bersztel A, Wadström J, Tufveson G, Gannedahl G, Bengtsson M, Bergström C, Frödin L, Claesson K, Wikström B, Wahlberg J. Is kidney transplantation in sensitized recipients justified? Transpl Int 1996; 9 Suppl 1:S49-53. [PMID: 8959790 DOI: 10.1007/978-3-662-00818-8_14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The objective of the study was to determine if it is justified to use the scarce resources of cadaveric kidneys on HLA-sensitized patients, by reviewing the initial and long-term outcome of cadaveric renal transplantation at Uppsala University Hospital, Sweden. Between January 1988 and December 1994, 402 renal transplantations were performed. The patients were divided into one group of sensitized recipients (peak panel antibody reactivity > or = 25%; n = 84) and a second of non-sensitized recipients (panel reactive antibodies < 25%; n = 318). The groups were comparable in terms of recipient and donor age, gender, HLA-A, -B and -DR mismatches and numbers of diabetics. None of the sensitized patients received a six-antigen-matched kidney. For the non-sensitized group, life table analysis showed a 1-year actuarial graft survival (GS) of 91.8% and a 4-year GS of 84.4%. The corresponding GSs for the sensitized group were 79.9% and 68.7%, respectively (P < 0.01). The statistical significance vanished if patients with primary non-function were excluded. When excluding donors above 55 years of age, kidneys with cold ischemia time above 20 h, and two-antigen (HLA-DR) mismatches, there was no detectable difference between the non-sensitized and sensitized groups at 1-year or 4-year GS. Although there is a statistical significance in GS between non-sensitized and sensitized recipients of a kidney transplant, this does not differ from other risk groups such as diabetics, rheumatoid disease sufferers or elderly recipients. We therefore conclude that the sensitized patient should be accepted on the waiting list for a kidney transplant and that it is worthwhile to do the utmost to transplant this category of patients. Our data indicate that kidney GS in sensitized recipients is more affected by negative risk factors such as older donors, long cold ischemia time and two-antigen HLA-DR mismatch, than the non-sensitized recipient. To improve the outcome, those negative factors should be avoided or reduced.
Collapse
Affiliation(s)
- A Bersztel
- Department of Transplantation Surgery, University Hospital, Uppsala, Sweden
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Bersztel A, Wanders A, Wadström J, Ekberg H, Olausson M, Tufveson G, Gannedahl G. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. Transplant Proc 1995; 27:3547. [PMID: 8540095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- A Bersztel
- Department of Transplantation Surgery, University Hospital, Uppsala, Sweden
| | | | | | | | | | | | | |
Collapse
|
12
|
Bersztel A, Wahlberg J, Gannedahl G, Claesson K, Wadström J. How safe is transplant nephrectomy? A retrospective study of 107 cases. Transplant Proc 1995; 27:3461-2. [PMID: 8540051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- A Bersztel
- Department of Transplantation Surgery, University Hospital, Uppsala, Sweden
| | | | | | | | | |
Collapse
|
13
|
Wadström J, Gannedahl G, Bersztel A, Bengtsson M, Nättorp K, Mulec H. Successful kidney transplantation after suppression of HLA alloantibodies with intravenous immunoglobulin in a highly sensitized patient. Transplant Proc 1995; 27:3463-4. [PMID: 8540052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- J Wadström
- Department of Transplantation Surgery, Akademiska Sjukhuset, Uppsala, Sweden
| | | | | | | | | | | |
Collapse
|